Global Career: From United States to Vietnam
At Nextern, we take pride in fostering global talent and creating opportunities for growth across our sites. In this month’s global career spotlight, we are highlighting Ryan, whose career journey at Nextern has grown and spanned from the United States to Vietnam.
Meet Ryan:
Ryan began his career in supply chain and operations management, building a strong foundation in strategic sourcing, logistics, and inventory planning. He joined Nextern as a Supply Chain Manager, overseeing global planning and purchasing. What drew him to Nextern was the entrepreneurial energy and opportunity to make a real impact in a growing company — something he hadn’t experienced at the large Fortune 500 companies he previously worked for.
“I liked that Nextern had an entrepreneurial spirit supported by a global manufacturing footprint. It felt like the right place to apply what I’d learned and continue growing,” Ryan shared.
Growth and Development at Nextern: A Bold Move to Vietnam
Ryan’s role and responsibilities have evolved significantly since joining. Supporting the opening of Nextern’s Vietnam site, leading product transitions, and navigating the challenges of COVID-19’s global supply chain disruptions helped sharpen his leadership skills and resilience. In 2022, Ryan took on a new challenge — relocating to Vietnam to serve as Site Director.
Professionally, the transition was smooth thanks to the support of his predecessor and Nextern’s leadership. Personally, it took time to adjust to a new culture, but his family soon felt at home.
One of the biggest lessons he’s learned is the importance of communication. “I had to learn to slow down, be mindful of cultural communication styles, and make sure I was truly being understood,” Ryan said.
Current Role & Impact
As Site Director, Ryan leads all day-to-day operations at Nextern Vietnam — from ensuring quality standards and financial performance to overseeing supply chain functions and resource allocation.
What excites him most about his role? “The team-first mentality. The Vietnam team takes pride in their work and are always ready to improve. I believe we have a foundation at the site that will continue to support Nextern’s overall growth as the site moves into single use, therapy delivery devices to support the already strong electro-mechanical portfolio that we have.”
Advice & Looking Ahead
Ryan encourages anyone considering an international career move to take the leap. “The experience has been life-changing both professionally and personally.”
As his time in Vietnam comes to a close, Ryan is preparing to return to the U.S. and continue contributing to Nextern’s growth in a supply chain leadership role. He’s excited to bring his international experience back home and continue supporting Nextern’s global manufacturing expansion.
Learn more about Who We Are
NextLEAP
A powerful end-to-end labeling automation solution to meet the rigorous demands of regulated industries.
Our Labeling Enterprise Automation Platform is a powerful end-to-end labeling automation solution designed to eliminate manual errors, streamline complex printing workflows, and reduce operational overhead in our manufacturing environments.
NextGUI
A system designed to accelerate time to market for medical devices with user interfaces.
This brochure outlines how our development team accelerates innovation with our own building blocks.
NextStim
A system designed to accelerate time to market for external wearable neurostimulation devices.
This brochure outlines how our development team accelerates innovation with our own building blocks.
How do you know if you are choosing the right CDMO for your Medical Device? Selecting the right Contract Development and Manufacturing Organization (CDMO) is one of the most critical decisions a medical device organization can make. Your partner will directly impact your product’s success, from early-stage development through commercialization. At Nextern, we go beyond traditional CDMO services to deliver vertically integrated, innovative, and scalable solutions designed for speed to market and long-term growth.
Key Factors in CDMO Selection
- Technical Expertise & Advanced Manufacturing
Your CDMO should possess deep knowledge of complex device development, from implantables, delivery systems, and single-use devices.
Nextern Advantage: Our expertise in precision engineering ensures your device is built to the highest standards.
- Seamless Design Transfer & Development Support
Efficient design transfer minimizes costly delays and ensures manufacturability without compromising innovation.
Nextern Advantage: Our cross-functional teams of engineers, regulatory experts, and manufacturing specialists collaborate to optimize your design for scalability and compliance.
- Regulatory & Quality Assurance
Your partner must have a strong track record in ISO 13485-certified manufacturing and regulatory compliance.
Nextern Advantage: Our FDA-registered facilities and robust quality management system (QMS) align with global regulatory requirements and FDA submissions.
- Flexible & Scalable Production Capabilities
As your business grows, your CDMO should scale production while maintaining quality and cost efficiency.
Nextern Advantage: Keeping commercialization in mind at the very beginning, we support our partners from conception through commercial launch and beyond.
- Speed to Market Without Sacrificing Quality
Timely delivery of clinical trial materials and commercial products is essential for success.
Nextern Advantage: Our lean manufacturing approach, in-house R&D, and vertically integrated solutions allow us to accelerate timelines without sacrificing quality.
- Strong Supply Chain & Risk Management
A reliable CDMO should proactively mitigate supply chain risks and ensure material availability.
Nextern Advantage: Our strategic supplier partnerships, strategic global locations and inventory management solutions ensure continuity in manufacturing.
- True Partnership & Transparent Communication
Beyond a vendor, your CDMO should act as an extension of your team, offering clear communication and collaborative problem-solving.
Nextern Advantage: We build long-term partnerships through dedicated project management, real-time reporting, and a collaborative approach that aligns with your strategic goals.
Why Choose Nextern as your CDMO Partner?
- Innovative & Customizable Solutions: We tailor our approach to meet your unique device requirements.
- Cost-Effective & Scalable Manufacturing: We align with your financial roadmap to optimize costs at every stage.
- Global Regulatory & Market Readiness: Our regulatory expertise ensures smooth global market entry.
- Agile & Responsive Team: We act as an extension of your business, committed to your success.
- End-to-End Development & Manufacturing: From concept to commercialization, Nextern supports your full product lifecycle.
Let’s Build the Future of Medtech Together. Partner with Nextern for a seamless, strategic, and scalable manufacturing solution. Contact us today to explore how we can bring your device to market faster and with greater impact.
Nextern Overview
Since 2000, Nextern has been a collaborative medical device company specializing in cutting-edge product design, development, and manufacturing. As a strategic partner, Nextern provides end-to-end services including concept development, design for manufacturability (DFM), technology transfer, and commercial-scale production of medical devices.
With a global footprint, Nextern operates facilities in Vietnam, Costa Rica, China, and the United States, offering vertically integrated solutions combining engineering expertise and advanced manufacturing capabilities. Nextern’s core competencies include electromechanical devices: Power Systems, Bioelectronic Devices, and Connected Devices, along with Single-Use Disposables (SUDs), and rapid prototyping services.
Our Minnesota-based development team includes a multidisciplinary staff covering mechanical, electrical, software, and systems engineering to adapt to project needs. Nextern’s global manufacturing operations feature a scalable, skilled labor force enabling efficient production and the ability to meet evolving customer demands. Operating under a unified electronic Quality Management System (QMS), Nextern is ISO 13485 certified, and BSI notified, ensuring compliance with global regulatory standards.
Brain-Computer Interfaces (BCIs) are a revolutionary technology enabling direct communication between the brain and external devices, offering transformative possibilities in medical technology. These devices could change the way we approach neurological conditions and enhance human-machine interaction. BCIs hold immense potential, particularly in improving the mobility of paraplegics, communication, and rehabilitation for individuals with neurological impairments.
The Science Behind BCIs
BCIs work by capturing and interpreting neural activity. Electrical signals from neurons can be recorded non-invasively with EEG or more precisely with implanted ECoG electrodes. Alternatively, fMRI and MEG track brain activity through blood flow and magnetic fields, although these are less practical for everyday use. Machine learning and AI refine these signals, translating them into commands and improving their accuracy over time. As technology advances, BCIs are becoming more efficient, expanding their potential applications in medicine, communication, and human augmentation.
Applications of BCIs in Medical Devices
Prosthetics and Mobility Aids: BCIs can significantly enhance the functionality of prosthetic limbs, allowing for more natural and intuitive control. This can dramatically improve the quality of life for amputees and individuals with spinal cord injuries.
Communication Aids: For patients with conditions like ALS (Amyotrophic Lateral Sclerosis), BCIs can provide a means of communication, translating thought patterns into speech or text, thus offering a vital lifeline for expression and interaction.
Neurorehabilitation: BCIs can facilitate neurorehabilitation by promoting neural plasticity. By using BCIs in conjunction with physical therapy, patients recovering from strokes or traumatic brain injuries can potentially regain lost functions more effectively.
As BCIs evolve, companies like Neuralink and OpenBCI are working on consumer-grade devices for applications in gaming, focus enhancement, and virtual reality. The U.S. military is also exploring BCIs to improve communication between soldiers, control drones, and enhance cognitive performance under stress.
Challenges and Future Directions
Despite their promise, BCIs face several challenges, including the need for more advanced signal processing algorithms, better hardware miniaturization, and addressing ethical concerns related to privacy and security. Future research and development are focused on overcoming these obstacles to make BCIs more accessible and effective.
Brain-Computer Interfaces represent a groundbreaking step in how humans interact with technology, with the potential to not only change lives but revolutionize fields like medicine, communication, and cognitive enhancement. While current applications are largely medical, advancements in AI, neural engineering, and signal processing are pushing BCIs toward more mainstream use. However, technical limitations and ethical concerns must be addressed to ensure their responsible integration. With careful regulation and innovation, BCIs could redefine how humans interact with technology, unlocking new possibilities for accessibility, productivity, and cognitive enhancement.
Looking to bring your BCI to market?
Nextern has the engineering expertise in BCI development and strategic global manufacturing locations to support your product at all stages. From concept to commercialization, we can work with you to solve your device complexities and bring it to launch. At Nextern, our team focuses on innovation in med-tech and technologies that revolutionize the space, like brain-computer interfaces – with an in-depth understanding of all the considerations that go into them, like connectivity, miniaturization, and electrode placement.
Sources:
“Brain-Computer Interfaces: From Basic Research to Clinical Use” – National Center for Biotechnology Information (NCBI)
“The Future of Brain-Computer Interfaces: New Directions for Emerging Technologies” – Frontiers in Neuroscience
“Ethical Issues in Brain-Computer Interface Research” – Journal of Medical Ethics
For more insights into innovative medical device design and development, visit our blog.
Nextern Overview
Since 2000, Nextern has been a collaborative medical device company specializing in cutting-edge product design, development, and manufacturing. As a strategic partner, Nextern provides end-to-end services including concept development, design for manufacturability (DFM), technology transfer, and commercial-scale production of medical devices.
With a global footprint, Nextern operates facilities in Vietnam, Costa Rica, China, and the United States, offering vertically integrated solutions combining engineering expertise and advanced manufacturing capabilities. Nextern’s core competencies include electromechanical devices: Power Systems, Bioelectronic Devices, and Connected Devices, along with Single-Use Disposables (SUDs), and rapid prototyping services.
Our Minnesota-based development team includes a multidisciplinary staff covering mechanical, electrical, software, and systems engineering to adapt to project needs. Nextern’s global manufacturing operations feature a scalable, skilled labor force enabling efficient production and the ability to meet evolving customer demands. Operating under a unified electronic Quality Management System (QMS), Nextern is ISO 13485 certified, and BSI notified, ensuring compliance with global regulatory standards.
At Nextern, we take pride in fostering global talent and creating opportunities for growth across our sites. One such inspiring journey is that of Jose, whose career has spanned continents. From his early career in Nextern Costa Rica to his current role in Nextern Vietnam, Jose has embraced challenges and thrived in our ever-evolving environment.
Meet Jose:
Jose’s background is rooted in Environment, Health, and Safety (EHS) engineering, with a specialization in critical safe work practices. His expertise naturally aligned with facilities and maintenance operations, making him an asset in any manufacturing setting.
Jose’s journey with Nextern began as an EHS Engineer with additional responsibilities supporting manufacturing. His decision to join the company was driven by a desire to gain more experience in production management in manufacturing beyond his EHS expertise.
“I have a passion for doing things right, ensuring employee well-being, and continuously finding ways to improve processes without compromising safety,” Jose shares. His proactive mindset and strategic approach to problem-solving quickly set him apart.
Growth and Development at Nextern: A Bold Move to Vietnam
With an adventurous spirit and a passion for globalization, Jose made the decision to transition from Costa Rica to Vietnam. The move was fueled by his desire to apply his expertise in a new environment, contribute to global standardization, and immerse himself in a different culture.
“The experience has been incredible,” Jose says. “I love Vietnamese food and culture. Professionally, I was welcomed with open arms, and I immediately saw opportunities to enhance process standardization.”
What excites him most about working at Nextern Vietnam? “Connecting with people and applying my knowledge to improve production efficiency, reduce waste, and drive standardization,” he shares.
Looking Ahead: A Vision for Growth
Jose’s career aspirations include developing leadership skills, driving lean manufacturing principles, and eventually stepping into a global EHS management role.
“The only limits are the ones we place on ourselves. An international career move is daunting, but the growth and opportunities are unmatched. I encourage anyone considering it to embrace the challenge.”
With his resilience, adaptability, and passion for continuous improvement, Jose is a driving force in Nextern’s journey toward operational excellence. His story is a testament to the power of stepping outside one’s comfort zone and embracing new opportunities.
At Nextern, we are proud to have team members like Jose who embody our commitment to innovation, collaboration, and global growth.
Learn more about Who We Are and What We Do
Nextern Overview
Since 2000, Nextern has been a collaborative medical device company specializing in cutting-edge product design, development, and manufacturing. As a strategic partner, Nextern provides end-to-end services including concept development, design for manufacturability (DFM), technology transfer, and commercial-scale production of medical devices.
With a global footprint, Nextern operates facilities in Vietnam, Costa Rica, China, and the United States, offering vertically integrated solutions combining engineering expertise and advanced manufacturing capabilities. Nextern’s core competencies include electromechanical devices: Power Systems, Bioelectronic Devices, and Connected Devices, along with Single-Use Disposables (SUDs), and rapid prototyping services.
Our Minnesota-based development team includes a multidisciplinary staff covering mechanical, electrical, software, and systems engineering to adapt to project needs. Nextern’s global manufacturing operations feature a scalable, skilled labor force enabling efficient production and the ability to meet evolving customer demands. Operating under a unified electronic Quality Management System (QMS), Nextern is ISO 13485 certified, and BSI notified, ensuring compliance with global regulatory standards.
At Nextern, we are committed to continuously expanding our expertise to better serve the medical device industry. By enhancing our vertically integrated capabilities, we take greater control over the manufacturing process, providing our partners with increased visibility and efficiency throughout the supply chain. This strategic approach adds value and ensures a streamlined path to market for their products.
So, what exactly does Vertical Integration mean?
Vertical integration is a business strategy that allows a company to streamline its operations by taking ownership of multiple stages of production thereby cutting out external contractors and suppliers. This allows companies to be completely in control of all or most components of the supply chain from raw material to finished good.
How is Nextern a Vertically Integrated company?
At Nextern, we continuously seek opportunities to expand both upstream and downstream, reducing reliance on suppliers and contractors while enhancing control over our operations. Forward vertical integration extends our capabilities closer to the commercial or consumer end of the supply chain. A key example is the addition of full sterile packaging capabilities at our Costa Rica facility, allowing us to deliver market-ready inventory directly to our collaborators. Backward integration, on the other hand, brings more of the manufacturing process in-house by moving closer to raw material production. Recently, we achieved the ability to form and bond balloons to catheters, eliminating the need for external suppliers and giving us full control over the balloon catheter manufacturing process.
Why is working with a Vertically Integrated Medical Device Manufacturer an advantage?
Reduced Margin:
Every supplier and contractor adds a profit margin to their time and materials, leading to multiple layers of markups throughout the manufacturing process. With each additional company involved, these costs compound, driving up the final unit price. By working with a vertically integrated partner, these extra margins are minimized, significantly reducing overall production costs. While there is still a margin on the actual cost of production, it is a single, streamlined markup rather than multiple, compounding price increases.
Lead Time Efficiencies:
Vertically integrated companies are highly favorable in medical device manufacturing because they streamline lead times and improve overall timeline efficiencies. By controlling multiple stages of the supply chain, from material sourcing to component production to final assembly and packaging, dependency on third-party suppliers is minimized and delays caused by external disruptions are reduced. This level of control allows for faster iteration cycles, improved quality management, and more efficient coordination between design, development, and manufacturing teams.
Additionally, vertical integration enables quicker responses to regulatory requirements and market demands, ensuring that products reach commercialization faster while maintaining compliance with industry standards. In a field where time to market is critical, this operational efficiency provides a significant competitive advantage.
Quality Assurance:
Quality control is a critical advantage of vertical integration in medical device manufacturing, ensuring consistency, reliability, and compliance throughout the production process. By keeping key component manufacturing and assembly stages in-house, companies can enforce stringent quality standards, reducing variability and the risk of defects that could lead to product recalls or regulatory issues.
Integrated operations also enable real-time monitoring, quicker identification of potential issues, and seamless coordination between design, engineering, and production teams to address quality concerns proactively. Maintaining control over sourcing, assembly, and testing ensures full traceability and adherence to FDA, ISO, and other industry standards. This level of oversight not only improves patient safety but also enhances the company’s reputation and long-term market success.
Nextern’s Vertically Integrated Processes:
Nextern acts as a collaborator to bring concepts to commercialization using a vertically integrated approach. From design and development work to supply chain and manufacturing optimization, we deliver end-to-end solutions that empower innovation and elevate patient care.
Late this summer, we consolidated our White Bear Lake and Maple Grove locations into a single facility in Arbor Lakes Business Park. We’re excited to share a look inside as we expand our capabilities in medical device contract design & manufacturing, all with a focus on quality, regulatory compliance, and client collaboration.
This new space represents a significant investment in expanding our cleanroom, warehouse, office, and manufacturing areas, allowing us to meet the unique needs of minimally invasive devices, power systems, and bioelectronics. Every aspect of our interior design was created to inspire collaboration and drive impact—values we hold at the core of our work here at Nextern.
As you enter, our client café welcomes visitors into a setting where ideas and innovation come together. Adjacent conference rooms lead directly into specialized spaces like our biosimulation lab, supporting the seamless transition from strategic planning to hands-on device testing. Beyond this, our open-concept office allows for easy collaboration among team members, ensuring fluid communication and efficiency.
With a commitment to integrity in everything we do, this facility reflects the Nextern way: to inspire with passion, impact with significance, and act with integrity. Swipe through to get a closer look at the spaces where ideas are brought to life and medical innovation is made possible.
Follow us on linkedin!
Stay in Touch
Sign up to receive updates and information about Nextern!
The rise of GLP-1 drugs has sparked a healthcare revolution, promising weight loss and improved glucose control with just a single injection. But what does this mean for medical devices that once dominated these treatment spaces?
What are GLP-1’s?
Glucagon-like peptide-1 (GLP-1) drugs are a new class of treatments originally designed to improve blood sugar control in individuals with type 2 diabetes by mimicking the natural GLP-1 hormone. This hormone prompts the body to produce insulin in response to rising blood sugar levels and prevents the release of glucagon which stops the release of glucose from the liver. Recently, GLP-1 drugs have also been approved for weight loss, as they help suppress appetite and slow digestion, leading to a surge in prescriptions for individuals struggling with obesity. With type 2 diabetes becoming more manageable and significant weight loss achievable through medication, GLP-1 drugs are poised to transform the landscape for medical devices used in treating diabetes, obesity, and related health conditions.
How will GLP-1 Drugs Affect Medical Device Landscape?
In 2022, obesity contributed to higher incidence and mortality rates for 8 of the 10 leading causes of death in the U.S., including heart disease, cancer, COVID-19, stroke, chronic lower respiratory diseases, diabetes, kidney disease, and chronic liver disease (CDC, 2022). With the rising popularity of GLP-1 drugs, however, the prevalence of these conditions may significantly decrease, potentially shrinking the market for related medical devices. On the other hand, as obesity rates fall, more patients may become eligible for life-saving procedures and live longer, introducing new opportunities for the medical device industry.
Market Challenges and the Shift Toward Non-Invasive Monitoring
As the incidence of type 2 diabetes continues to decrease, the demand for continuous glucose monitors and insulin pumps—a traditionally lucrative segment of the medical device industry—will likely decline. This shift towards pharmacological treatments, particularly with the rise of GLP-1 drugs, could profoundly impact market leaders who have long relied on diabetes management devices as their primary industry. With a reduced patient pool consisting of individuals with type 1 diabetes—who make up only 5-10% of all diagnosed diabetes cases—the market dynamics for these devices may face a significant transformation, challenging the long-established dominance of these companies. Looking ahead, the future of diabetes management will increasingly focus on non-invasive monitoring devices, reflecting a broader trend in the medical device industry where remote monitoring is becoming the standard of care.
Examining the diabetes market is just the tip of the iceberg. While diabetes is directly impacted by the GLP-1 boom, what about the other conditions that will see a reduction as obesity rates continue to decline?
Case Study: Sleep Apnea
Sleep apnea is a disorder that causes affected individuals to repeatedly stop breathing during sleep due to the muscles in the throat relaxing and narrowing the airway which puts strain on the heart and leads to chronic fatigue. An estimated 30-39 million Americans are affected by sleep apnea, making it one of the most prevalent medical conditions in the country (National Council on Aging, n.d.). Obesity is a key risk factor for sleep apnea, making it a disorder that could potentially be alleviated by the weight loss effects of GLP-1 drugs.
Current Treatments and Emerging Impacts of GLP-1 Drugs on Sleep Apnea Management
Common treatment options for sleep apnea include using a continuous positive airway pressure (CPAP) machine or undergoing surgery to remove tonsils, adenoids, or nasal polyps that may obstruct the airway during sleep. Additionally, alternative treatments that stimulate the muscles in the tongue and throat to help keep the airway clear are available, including implants or external stimulators. Looking ahead, the GLP-1 boom is expected to decrease the incidence of sleep apnea through weight loss, while also allowing more patients to qualify for procedures to treat the condition. Critically obese patients are often not approved for non-life-saving surgery due to the risks associated with anesthesia, but with reduced weight, they may become candidates for these treatments. While the market value of sleep apnea treatment devices is not likely to shift significantly as the condition cannot be cured solely by losing weight, the treatment type may shift towards implantables rather than CPAPs as more of the patient pool becomes eligible for surgery.
Case Study: Orthopedics
Orthopedic issues, particularly degenerative joint conditions like osteoarthritis, are prevalent in individuals with obesity and often lead to joint replacement surgeries. Conditions such as hip and knee osteoarthritis are strongly linked to excess body weight, as the added stress on joints accelerates wear and tear. In the U.S., an estimated 54 million adults have arthritis, and nearly half of these individuals report activity limitations due to joint pain or mobility issues, with obesity being a key risk factor (CDC, 2024). But, the rise of GLP-1 drugs offers new hope for those who struggle with obesity-related joint issues. With more people achieving significant weight loss through these drugs, the pressure on load-bearing joints like the knees and hips may decrease, potentially slowing the progression of arthritis. For the orthopedic industry, this could mean a decreased demand for certain types of joint replacement surgeries in the long term, as fewer patients may reach the point where surgical intervention is necessary. Additionally, earlier weight management could reduce the severity of joint damage in younger patients, pushing back the age at which they may require surgery.
Shifting Demand for Joint Replacements and Expanding Surgical Eligibility
On the other hand, there’s also potential for an expanded market. As more people achieve a healthier weight, patients who were previously high-risk for surgery due to obesity-related complications may now qualify as candidates for joint replacements. Traditionally, obesity increases the risks associated with joint replacement surgeries, including complications with anesthesia, higher infection rates, and longer recovery times. As patients reach healthier weights through GLP-1-supported weight loss, orthopedic surgeons may have a broader pool of candidates eligible for these life-improving procedures. This shift could lead to increased demand for joint replacement surgeries among once ineligible patients, creating new growth opportunities for orthopedic device companies. Innovations in implant design and minimally invasive procedures, which reduce recovery times and further lower surgical risks, will be essential as this new demographic of patients becomes eligible for joint replacement options.
Conclusion:
GLP-1s are making significant strides in the pharmaceutical world, and there’s little doubt they will enhance the quality of life for many patients, particularly those battling obesity and type 2 diabetes. However, as these drugs continue to rise in popularity, they also raise an important question: How will their widespread use impact the existing technologies that aim to treat common diseases and disorders?
Adapting to the GLP-1 Revolution in Healthcare
At Nextern, we are excited to see how these innovations will shape the future of healthcare, particularly in driving the industry toward more non-invasive monitoring and treatment solutions. As a contract development and manufacturing firm with deep expertise in these areas, we’re committed to staying ahead of the curve. The changes GLP-1s are introducing to the medical device landscape present both challenges and opportunities, and we’re prepared to adapt and collaborate with our partners to develop the next generation of medical devices that can complement these advancements.
We look forward to seeing how this evolving landscape will open new possibilities for improving patient care, and we are enthusiastic about the role we will play in shaping that future.
Medical Device Enabled.
Looking to advance your next project? Nextern enables partner medical device innovators to plan, design, build, and manufacture medical devices that are changing the world. Our team of experienced engineers, technicians, and designers collaborate to bring ideas, prototypes, or existing products to market faster – contact us today for your project needs.
Follow us on linkedin!
Stay in Touch
Sign up to receive updates and information about Nextern!
